Clinigen Group PLC | Ownership
Companies that own Clinigen Group PLC
AXA Investment Managers UK Ltd.
10,895,426
8.91%
4,026,324
0.53%
11/01/2017
Old Mutual Global Investors (UK) Ltd.
7,717,770
6.31%
273,848
0.28%
06/29/2018
Rathbone Investment Management Ltd.
6,724,237
5.5%
176,191
0.42%
10/31/2017
Wasatch Advisors, Inc.
5,451,421
4.46%
455,236
0.46%
08/28/2017
Octopus Investments Ltd.
5,188,234
4.24%
32,758
2.93%
11/03/2017
Henderson Global Investors Ltd.
4,159,449
3.4%
-32,322
0.02%
10/30/2017
BAE Systems Pension Funds Investment Management Ltd.
4,077,306
3.33%
-30,661
1.5%
11/06/2017
Standard Life Investments Ltd.
3,635,298
2.97%
-1,785,902
0.08%
02/08/2016
NFU Mutual Investment Services Ltd.
3,108,465
2.54%
-385,094
0.65%
08/29/2017
Baillie Gifford & Co.
2,630,507
2.15%
885,729
0.02%
11/01/2017
| Address |
Pitcairn House
Burton-on-Trent Staffordshire DE14 2WW
United Kingdom
|
|
Employees
|
- |
| Website |
http://clinigen.co.uk |
| Updated |
07/08/2019 |
| Clinigen Group Plc engages in the provision of pharmaceutical products and services. It operates through the following segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA), Clinigen Specialty Pharmaceuticals (SP), and Link Health Care. The Clinigen CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. |
